Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

THROMBIN INHIBITOR ARGATROBAN SHOWS ZERO PERCENT REOCCLUSION RATE

Executive Summary

THROMBIN INHIBITOR ARGATROBAN SHOWS ZERO PERCENT REOCCLUSION RATE versus 15% reocclusion rate in patients receiving heparin after successful reperfusion therapy, a study sponsored by Daiichi Pharmaceutical shows. The study was presented Nov. 17 at the American Heart Association's 65th Scientific Sessions in New Orleans. An abstract of the study states: "The rate of reocclusion of infarct-related artery within one month was 0% in [patients taking argatroban] and 15% in [patients taking heparin]." The objective of the study was to evaluate the selective thrombin inhibitor argatroban's efficacy in preventing reocclusion after reperfusion therapy in patients with acute myocardial infarction, study investigator Hirotsugu Tabata, National Defense Medical College, Saitama, Japan, reported. He explained that coronary reocclusion after reperfusion therapy occurs in 10% to 15% of patients. A total of 35 patients with acute myocardial infarction (AMI) were given argatroban and 74 patients with AMI were given heparin 72 hours after successful reperfusion therapy with thrombolytics or angioplasty. "In the argatroban group, the frequency of reocclusion after [reperfusion] therapy was significantly lower than the heparin group," Tabata concluded. "No complications, such as massive bleeding" were recorded in the argatroban group, Tobata said. He noted that two patients treated with heparin had massive bleeding from puncture sites, "which needed transfusion." Tabata pointed out that unlike heparin, argatroban "doesn't have natural inhibitors and is effective for clot-bound thrombin." Argatroban was jointly developed by Daiichi, Mitsubishi Kasei and the University of Kobe, Japan. Genentech licenses U.S. and Canadian marketing rights to argatroban from Mitsubishi Kasei. Genentech said it has completed a Phase I study of argatroban and is considering future directions for the agent.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021849

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel